China Initiative for Diabetes Excellence (CIDE) Program

Partnership objective

Promote the capability development of young Chinese endocrinology experts, county and community doctors to provide the best care for diabetic patients in China.

Scientific exchanges through this program has shown that positive capacity building and transfers of knowledge could be achieved successfully. Scientific exchanges through this program has shown that positive capacity building and transfers of knowledge could be achieved successfully. Copyright Sanofi

What are the health needs and challenges?

China has the largest population of diabetics in the world and is confronted with a real epidemic of the disease. However, the direct treatment of Type 2 diabetes and its complications in urban China only amounts to 3.94% of the total amount of health budget. In addition, according to the International Diabetes Federation, one in two adults with diabetes is undiagnosed and unaware of their disease.

Description of partnership activities and how they address needs and challenges

As a pioneer in the field of diabetes, Sanofi supports a number of initiatives in China. The China Initiative for Diabetes Excellence (CIDE) program is a five-year disease management program led by the Chinese Heath Ministry. This strong public-private partnership between Sanofi and the Chinese Diabetes Society (CDS), the Centre of Disease Control (CDC) and the World Health Organization (WHO) Collaborating Center at the International Diabetes Center intends to provide diabetic patients with the best care possible, by providing world-class clinical and research training programs. 

The program rolls out in several phases:

  • Promote the capability development of young Chinese endocrinology experts by conveying basic notions of public health and reinforcing their capacity to collaborate with local doctors in providing the best possible health care to diabetic patients.
  • Train community and county doctors to give them the skills needed to optimize resources on the ground.  
  • Additionally train CDC staff at provincial level and regional level to enhance their understanding about Chinese diabetes prevention and management.

This program shows that there is a need to provide a high level educational programs in a country where the incidence and prevalence of diabetes in growing. Scientific exchanges through this program has shown that positive capacity building and transfers of knowledge could be achieved successfully in this country. 

Over the past five years, CIDE :

1, Strengthened international exchanges and introduced the concept of international advanced IDC clinical treatment concept to China.

2, Improved the level of diagnosis and treatment of professional doctors in the field of diabetes in China, including doctors of the top city hospitals, as well as basic level hospital (county level hospitals) of the general practitioner

3, Helped public health management officials (CDC) to improve the awareness of chronic disease management, and published the chronic disease management guidelines for public health at all levels in the country, promoting in CDC level. 

This was achieved through the training of over 450 young Chinese experts in endocrinology, about 25000 county and community doctors, about 140 CDC staff at provincial level and 2500 CDC staff at regional level. In addition, 50 Chinese endocrinology experts were sent to IDC and Mayo Clinic for exchange and learning. 

Partnership information

Company(ies) Sanofi

Partner(s) CDC China, Chinese Diabetes Society, Chinese Ministry of Health, World Health Organization (WHO)

Type of Partner(s) Government, IGOs

Therapeutic Focus Non-Communicable Diseases

Disease(s) Diabetes

Program Type(s) Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Targeted Population(s) Health professionals

Region(s) East Asia & Pacific

Number of Countries 1

Country(ies) China

Start Date 2011

More information Press Release (fr)

Anticipated completion date 2016

« This innovative program is a decisive step in our fight against a major public health threat in China. It rests on a unique partnership between specialists, local doctors, and patients, and fits with the health care reform initiated in China. »

Lei Zhenlong, Director General of the Office for Disease Prevention and Control within the Chinese Health Ministry